Acarix A/S (ACARIX)

Currency in SEK
0.2870
+0.0165(+6.10%)
Closed·
ACARIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.27600.2945
52 wk Range
0.19140.4710
Key Statistics
Prev. Close
0.2705
Open
0.2905
Day's Range
0.276-0.2945
52 wk Range
0.1914-0.471
Volume
558.18K
Average Volume (3m)
1.66M
1-Year Change
15.9596%
Book Value / Share
0.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACARIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Acarix A/S News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Acarix A/S Company Profile

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

Acarix A/S Earnings Call Summary for Q3/2025

  • Acarix reported Q3 2025 revenue of 2.35M SEK (+137% YoY), reduced net loss by 49% to 9.4M SEK, and cut operating expenses by 43%, driving a 3.59% stock price increase.
  • The company's CADScore System deployment grew 95% QoQ with patch sales up 80% YoY, while gross margin declined by 5 points to 85%.
  • Acarix is expanding its addressable market from $6B to $22B, with strategic focus on the US market and rural health initiatives through the CMS Rural Health Transformation Program.
  • New product development includes the GADSCORE device and heart failure diagnostic algorithm, positioning the company for continued growth in cardiovascular diagnostics.
  • Management anticipates potential financing in 2026 and is pursuing global distribution partnerships while continuing clinical trials to support reimbursement expansion.
Last Updated: 11/06/2025, 05:50 PM
Read Full Transcript

Compare ACARIX to Peers and Sector

Metrics to compare
ACARIX
Peers
Sector
Relationship
P/E Ratio
−6.4x17.5x−0.5x
PEG Ratio
−0.130.480.00
Price/Book
8.7x7.8x2.6x
Price / LTM Sales
48.5x5.9x3.3x
Upside (Analyst Target)
47.9%16.0%45.0%
Fair Value Upside
Unlock10.7%5.1%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
2.40M / 2.30M
EPS Revisions
Last 90 days

ACARIX Income Statement

FAQ

What Is the Acarix (ACARIX) Stock Price Today?

The Acarix stock price today is 0.2870

What Stock Exchange Does Acarix Trade On?

Acarix is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Acarix?

The stock symbol for Acarix is "ACARIX."

What Is the Acarix Market Cap?

As of today, Acarix market cap is 351.70M.

What Is Acarix's Earnings Per Share (TTM)?

The Acarix EPS (TTM) is -0.05.

When Is the Next Acarix Earnings Date?

Acarix will release its next earnings report on Feb 11, 2026.

From a Technical Analysis Perspective, Is ACARIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Acarix Stock Split?

Acarix has split 2 times.

How Many Employees Does Acarix Have?

Acarix has 8 employees.

What is the current trading status of Acarix (ACARIX)?

As of Feb 10, 2026, Acarix (ACARIX) is trading at a price of 0.2870, with a previous close of 0.2705. The stock has fluctuated within a day range of 0.2760 to 0.2945, while its 52-week range spans from 0.1914 to 0.4710.

What Is Acarix (ACARIX) Price Target According to Analysts?

The average 12-month price target for Acarix is SEK0.4000, with a high estimate of SEK0.4 and a low estimate of SEK0.4. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +39.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.